Immunexpress to Present Data on the Early Diagnosis of Sepsis with SeptiCyte® Lab at the Next Generation Diagnostics Summit

Aug 12, 2015, 08:00 ET from Immunexpress, Inc.

SEATTLE, Aug. 12, 2015 /PRNewswire/ -- Immunexpress, Inc. today announced that Dr. Therese Seldon, Vice President of Operations, will present data on the utility of its SeptiCyte® Lab test to aid in the clinical assessment of sepsis in critical care patients at the Next Generation Diagnostics Summit on Aug. 19 in Washington, D.C. The presentation will include data from a large, prospective, multisite study.

  • Oral presentation: "A Molecular Host Response Assay to Discriminate Between Infection-Positive and Infection-Negative Systemic Inflammation in Critically Ill Patients"

Session: New and Improved Molecular Testing – Clinical Application and Evaluation
Presenter: Dr. Therese Seldon
Date: Wednesday, Aug. 19
Time: 3:30 p.m. EDT

Additional information may be found at http://www.nextgenerationdx.com/infectious-disease-diagnostics

Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Sepsis diagnostics today aim to identify the pathogen only and therefore have serious limitations in respect of speed and sensitivity. The Immunexpress SeptiCyte® solution evaluates the host immune response to aid clinicians in quickly and accurately diagnosing sepsis.

About SeptiCyte® Lab

SeptiCyte® Lab quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Immunexpress has validated hundreds of nucleic acid and protein expression biomarkers that, in different combinations, answer specific clinical questions about sepsis. Patented biomarkers, algorithms and analysis methods are used to interpret information about the septic host response.

About Immunexpress

Immunexpress is a molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's core competency is the clinical validation and commercialization of genomic and proteomic biomarkers and the translation of these novel biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. Immunexpress is based in Seattle.  For more information visit www.Immunexpress.com.

Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com

SOURCE Immunexpress, Inc.



RELATED LINKS

http://immunexpress.com